Repligen (RGEN) Tops Q1 EPS by 11c, Revenues Beat; Raises FY20 EPS Guidance Above Consensus, Reaffirms Revenue Views Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. IBM
5. ACN
6. NVDA
7. PRIM
8. META
9. SPY
10. TSLA

Go back to Repligen (RGEN) Tops Q1 EPS by 11c, Revenues Beat; Raises FY20 EPS Guidance Above Consensus, Reaffirms Revenue Views Above Consensus

Repligen Reports First Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance

May 6, 2020 7:30 AM EDT

Reports record quarterly revenue of $76.1 millionOverall revenue grew 25% year-over-year, with organic growth of 16% Strong order load through first four months

WALTHAM, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2020. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2020 and access information for todays webcast and conference call.

Tony J. Hunt,... More